Loading...
•
Mar 31, 2023
OmniAb Q1 2023 Earnings Report
Reported a strong start to the year with revenue increase and advancement in partner programs.
Key Takeaways
OmniAb reported a strong start to 2023, with revenue increasing to $16.9 million due to a $10.0 million milestone payment. The company reached 301 active programs, with 27 in clinical development or approved for commercialization.
Revenue for the first quarter of 2023 was $16.9 million, compared to $9.6 million for the same period in 2022.
Net loss for the first quarter of 2023 was $6.1 million, or $0.06 per share, compared to a net loss of $6.3 million, or $0.08 per share, for the same period in 2022.
As of March 31, 2023, OmniAb had cash, cash equivalents and short-term investments of $113.6 million.
The company reached 301 active programs, with 27 in clinical development or approved for commercialization.
OmniAb
OmniAb
OmniAb Revenue by Segment
Revenue by Segment
License and milestone Revenue
CapyFin.comService Revenue
CapyFin.comRoyalty Revenue
CapyFin.com Forward Guidance
The Company expects its year-end 2023 cash, cash equivalents and short-term investments balance to be slightly higher than year-end 2022. Current cash, cash equivalents and short-term investments, along with the cash the Company generates from operations, are expected to be sufficient to fund operations for the foreseeable future.
Revenue & Expenses
Visualization of income flow from segment revenue to net income